GCC Nursing Guide — Type 2 Diabetes Management

What is Type 2 Diabetes?

Type 2 Diabetes Mellitus (T2DM) is characterised by a combination of insulin resistance (cells fail to respond to insulin) and relative insulin deficiency (pancreatic beta-cell exhaustion over time). Unlike T1DM, insulin production is present but insufficient or ineffective.

15–25%GCC Prevalence

≥7 mmol/LFasting Glucose Dx

≥48 mmol/molHbA1c Dx (6.5%)

BMI >25Major Risk Factor

Pathophysiology: Adipokines from visceral fat impair insulin signalling. Glucotoxicity and lipotoxicity further damage beta cells. Incretin deficiency (reduced GLP-1 response) contributes. The "ominous octet" (DeFronzo) includes 8 organ defects: muscle, liver, fat, pancreas (beta + alpha cells), kidney, brain, gut, and incretin axis.

Risk Factors

BMI >25 kg/m² (overweight/obese)
Central obesity (waist ≥94 cm men, ≥80 cm women)
Family history of T2DM (first-degree relative)
Gestational diabetes mellitus (GDM) history
Polycystic ovary syndrome (PCOS)
Hypertension, dyslipidaemia
Physical inactivity; high-calorie diet
Ethnicity: South Asian, Middle Eastern, African heritage
Age >45 years (risk increases with age)
Impaired fasting glucose or impaired glucose tolerance (pre-diabetes)

Diagnostic Criteria (WHO/ADA)

Test	Diagnostic Threshold
Fasting plasma glucose (FPG)	≥7.0 mmol/L
2-hour OGTT (75g glucose)	≥11.1 mmol/L
Random plasma glucose + symptoms	≥11.1 mmol/L
HbA1c	≥48 mmol/mol (6.5%)
Pre-diabetes FPG	6.1–6.9 mmol/L
Pre-diabetes HbA1c	42–47 mmol/mol

Note: A single abnormal result in a symptomatic patient is sufficient. In asymptomatic patients, a second confirmatory test is required unless HbA1c ≥48 mmol/mol (confirmed on two separate occasions).

HbA1c Targets

Patient Group	HbA1c Target	Rationale
General adult with T2DM	<53 mmol/mol (7%)	Balances glycaemic control with hypoglycaemia risk
Young patient, newly diagnosed, low complication risk	<48 mmol/mol (6.5%)	Tight control when safe and feasible
Elderly / complex / frail / multiple comorbidities	<64 mmol/mol (8%)	Avoids hypoglycaemia risk in vulnerable patients
Pre-pregnancy (T2DM)	<48 mmol/mol (6.5%)	Minimise congenital anomalies and miscarriage

Clinical Assessment Framework

A structured assessment guides individualised management. Include both glycaemic and cardiovascular risk profiles.

History

Duration of diabetes, age at diagnosis, prior treatments
Symptoms: polyuria, polydipsia, polyphagia, weight loss, fatigue, blurred vision, recurrent infections
Hypoglycaemia awareness: frequency, triggers, severity, nocturnal episodes
Self-monitoring: SMBG frequency, glucose log review
Diet history, alcohol intake, physical activity level
Medications: current, adherence, intolerances, OTC/herbal remedies
Complication screening: feet, eyes, kidney, cardiovascular symptoms
Family history, social circumstances, employment, driving licence

Physical Examination

Weight, BMI, waist circumference
Blood pressure (both arms, lying/standing for autonomic neuropathy)
Foot examination: monofilament, vibration, pulses, ABI, skin integrity
Injection site inspection: lipohypertrophy, bruising, infection
Fundoscopy / retinal screening referral if not done within 12 months

Essential Investigations

HbA1c — every 3 months until stable, then 6-monthly
Fasting lipid profile (total cholesterol, LDL, HDL, TG)
eGFR + serum creatinine — at least annually
Urine albumin:creatinine ratio (ACR) — annually
LFTs — before starting metformin; monitoring with fatty liver
Thyroid function (TFT) — if suspected thyroid dysfunction
Vitamin B12 — if on long-term metformin (risk of deficiency)
ECG — cardiac risk assessment

Foot Assessment — Monofilament & ABI

Monofilament testing (10g Semmes-Weinstein): 10 sites per foot. Inability to feel at ≥1 site = peripheral neuropathy. Test annually in all T2DM patients.

ABI (Ankle-Brachial Index): normal 0.9–1.3; <0.9 = peripheral arterial disease; >1.3 = calcified vessels
Vibratory sensation: 128 Hz tuning fork at hallux
Check between toes, heel, callus sites, pressure areas
Wagner classification for diabetic foot ulcers: Grade 0–5 (0=intact, 5=gangrene)
Diabetic foot infection = clinical emergency; urgent surgical/multidisciplinary review

Hypoglycaemia Assessment

Definition: Blood glucose level (BGL) <4.0 mmol/L. May occur with any glucose-lowering medication, especially sulphonylureas and insulin.

Level	BGL	Features	Action
Level 1	3.0–3.9 mmol/L	Sweating, tremor, palpitations, hunger — adrenergic symptoms	15g rapid carbohydrate, recheck at 15 min
Level 2	<3.0 mmol/L	Confusion, neuroglycopenia, cognitive impairment	Immediate treatment, close monitoring
Level 3 (Severe)	Any level	Requires third-party assistance; seizure, unconsciousness	IV dextrose or IM glucagon

First-Line: Metformin

Metformin remains the foundation of T2DM pharmacotherapy. It improves insulin sensitivity primarily at the liver by reducing hepatic gluconeogenesis.

Indications & Benefits

First-line in all T2DM patients tolerated
Weight neutral to modest weight loss
Cardiovascular benefit (UKPDS)
Low hypoglycaemia risk as monotherapy
Low cost; widely available in GCC

Contraindications / Caution

eGFR <30 mL/min/1.73m² — STOP (lactic acidosis risk)
Hold for iodinated contrast media (restart 48h post-procedure)
Hold day of surgery + 48 hours post-op
Acute illness / dehydration (SADMAN rule)
Hepatic failure, alcohol excess
Review if eGFR 30–45: halve dose, caution

Cardiovascular & Renal Protective Agents

Drug Class	Examples	Key Benefits	Nursing Considerations
SGLT2 inhibitors	Empagliflozin, Dapagliflozin, Canagliflozin	Cardiovascular protection, heart failure benefit, renal protection, weight loss, BP reduction	STOP 3 days pre-surgery (euDKA risk); UTI/genital candidiasis; ensure adequate hydration; sick day rules apply
GLP-1 RA	Semaglutide (Ozempic/Wegovy), Liraglutide (Victoza), Dulaglutide	Weight loss (5–15%), cardiovascular benefit, postprandial glucose control, reduced appetite	Nausea common (dose-titrate); inject subcutaneously; rotate sites; refrigerate before opening; pancreatitis warning
DPP-4 inhibitors	Sitagliptin, Saxagliptin, Vildagliptin	Modest HbA1c reduction, weight neutral, low hypo risk	Dose-adjust for renal impairment; risk of joint pain; saxagliptin — caution in heart failure

GCC exam tip: SGLT2i and GLP-1 RA are now recommended as second-line (or first-line alongside metformin) in patients with established cardiovascular disease, heart failure, or CKD — regardless of HbA1c level.

Sulphonylureas & Other Agents

Drug Class	Examples	Key Points
Sulphonylureas (SU)	Gliclazide, Glibenclamide, Glimepiride	Stimulate insulin release; significant hypoglycaemia risk; weight gain; avoid in renal failure; STOP during SADMAN sick days
Thiazolidinediones	Pioglitazone	Insulin sensitiser (PPAR-γ); weight gain, fluid retention; AVOID in heart failure; fracture risk; bladder cancer risk (prolonged use)
Acarbose (alpha-glucosidase inhibitor)	Acarbose	Slows carbohydrate absorption; GI side effects; rarely used; treats postprandial spikes
Insulin	Basal (glargine, detemir), Mixed, Basal-bolus	Required when oral agents inadequate; start basal at 10 units nocte; titrate by 2U every 3 days to FBG target 4–7 mmol/L

SADMAN — Sick Day Rules

SADMAN mnemonic: During illness, vomiting, diarrhoea, or dehydration — temporarily STOP these medications to prevent acute kidney injury and other complications.

Letter	Drug Class
S	Sulphonylureas
A	ACE inhibitors
D	Diuretics
M	Metformin
A	ARBs (Angiotensin Receptor Blockers)
N	NSAIDs

Nursing Actions During Sick Day

Monitor BGL every 2–4 hours
Maintain fluid intake (water, clear fluids)
Check urine/blood ketones if BGL >14 mmol/L
Continue insulin (never stop in insulin-requiring T2DM)
Seek medical review if unable to maintain oral fluids
Restart medications when recovered and eating normally

Hypoglycaemia Treatment Protocol

Patient Status	Treatment	Recheck
Conscious, able to swallow	15g rapid-acting carbohydrate: 150–200 mL orange juice, 6 glucose tablets, 5 jelly beans, or 3 glucose gel sachets	Recheck BGL at 15 minutes. Repeat if still <4.0. Follow with long-acting carbohydrate (bread/biscuit) once BGL ≥4.0
Unconscious / cannot swallow	IV dextrose 10% 150 mL over 15 min (preferred) OR glucagon IM 1 mg (SC if IM not possible)	Recheck BGL after treatment. Establish IV access. Treat cause. Consider hospital admission
Hypoglycaemia unawareness	Relax glycaemic targets temporarily; avoid BGL <6 for 2–3 months; refer for structured education; consider CGM	Regular specialist review; DVLA/driving authority notification where applicable

Rule of 15: 15g carbohydrate → recheck at 15 minutes → if still <4, repeat. Do not over-treat (rebound hyperglycaemia).

Macrovascular Complications

Accelerated atherosclerosis due to chronic hyperglycaemia, hypertension, and dyslipidaemia. Leading cause of mortality in T2DM.

Myocardial Infarction (MI): 2–3× risk vs non-diabetics; may present silently (diabetic autonomic neuropathy masks pain)
Stroke/TIA: 2–3× risk; same early management — treat hyperglycaemia >10 with insulin in acute setting
Peripheral Arterial Disease (PAD): claudication, rest pain, absent pulses; ABI <0.9; critical limb ischaemia requires urgent vascular review

Risk Reduction

Antiplatelet therapy (aspirin/clopidogrel) where indicated
Statin therapy: LDL target <1.8 mmol/L in high CV risk
ACEi/ARB for hypertension + renal protection
Smoking cessation (doubles macrovascular risk)
SGLT2i/GLP-1RA for established CVD

Microvascular Complications

Complication	Pathophysiology	Screening	Management
Diabetic Retinopathy	Microaneurysms → haemorrhage → neovascularisation (proliferative retinopathy → vitreous haemorrhage, retinal detachment)	Annual dilated fundoscopy/retinal photography	Tight glycaemic + BP control; laser photocoagulation; anti-VEGF injections; vitrectomy for severe cases
Diabetic Nephropathy	Glomerulosclerosis (Kimmelstiel-Wilson lesions), increased GFR → microalbuminuria → proteinuria → declining eGFR	Annual ACR + eGFR; ACR >3 mg/mmol = microalbuminuria	ACEi/ARB (renoproductive); SGLT2i; BP <130/80; avoid nephrotoxic drugs; dietary protein restriction in advanced CKD
Diabetic Neuropathy	Axonal degeneration, demyelination. Distal symmetric polyneuropathy most common; autonomic, focal also occur	Annual monofilament + vibration; autonomic: postural BP, HR variability	Optimise glycaemia; duloxetine/pregabalin/amitriptyline for painful neuropathy; foot care education; TENS

Diabetic Foot — Wagner Classification

Diabetic foot emergency: Any signs of infection (warmth, redness, swelling, discharge, systemic features) in a diabetic foot = emergency multidisciplinary assessment required within 24 hours.

Grade	Description	Management
Grade 0	Intact skin; high risk (neuropathy/ischaemia present)	Prevention, education, appropriate footwear
Grade 1	Superficial ulcer, no infection	Wound care, offloading, debridement
Grade 2	Deep ulcer to tendon/capsule/bone — no abscess	Antibiotics, surgical debridement, MDT
Grade 3	Deep ulcer with abscess, osteomyelitis, or tendinitis	Hospitalisation, IV antibiotics, possible surgery
Grade 4	Partial foot gangrene	Surgical consultation; partial amputation may be required
Grade 5	Whole foot gangrene	Amputation; vascular surgery review

T2DM in the GCC Region

The GCC region has some of the highest T2DM prevalence rates globally, driven by rapid economic development, dietary changes (high-calorie processed foods), sedentary lifestyles, and genetic predisposition.

~25%Saudi Arabia Adults

~20%UAE Adults

~22%Kuwait Adults

Top 10Global Prevalence

Saudi Arabia — SDSC & National Diabetes Programme ▼

Saudi Arabia's Saudi Diabetes Society (SDS) and the Ministry of Health have established national diabetes care guidelines aligned with IDF and ADA standards. Key initiatives include:

National Diabetes Registry for epidemiological surveillance
Free diabetes medications under the national health programme
Mandatory HbA1c monitoring in all primary care facilities
Diabetes nurse educator certification (SCFHS-accredited)
School diabetes screening programmes
SCFHS exam includes T2DM pharmacology, complications, and Ramadan protocols

UAE — DHA & DOH Diabetes Protocols ▼

The Dubai Health Authority (DHA) and Department of Health (DOH) Abu Dhabi have comprehensive diabetes management pathways. DHA licensing exams test nurses on GCC-specific diabetes management including:

HAAD/DOH care standards for T2DM in primary care
Structured diabetes education programmes (DESMOND equivalent)
HbA1c target for UAE patients: <53 mmol/mol in most adults, relaxed to <64 in elderly
Bariatric surgery as T2DM treatment pathway for BMI ≥35 or BMI ≥30 with poor glycaemic control
Pre-Ramadan assessment clinics mandated in DHA-accredited facilities

Ramadan Fasting — Diabetes Management ▼

During Ramadan, Muslim patients with T2DM who choose to fast present unique clinical challenges. The DHA and Saudi MoH have issued specific Ramadan diabetes protocols.

Risk stratification before Ramadan:

Very high risk (advised NOT to fast): T1DM, recent DKA/HHS, severe hypoglycaemia unawareness, poorly controlled T2DM (HbA1c >10%), pregnancy with diabetes, acute illness
High risk: T2DM on insulin, sulphonylureas with poor control, renal failure, cognitive impairment
Moderate/Low risk: Well-controlled T2DM on diet alone, metformin, SGLT2i, GLP-1 RA, DPP-4i — generally safe to fast with monitoring

Medication adjustments during Ramadan:

Metformin: take at Iftar (sunset) and Suhoor (pre-dawn)
Sulphonylureas: REDUCE dose by 50%; take at Iftar only; highest hypoglycaemia risk at pre-sunset (late fasting)
SGLT2i: monitor dehydration and DKA risk; generally continue with caution
GLP-1 RA: generally safe; inject at Iftar
Insulin: basal dose may need 15–30% reduction; bolus timed with meals
Break fast immediately if BGL <3.9 mmol/L or >16.6 mmol/L
Consult diabetologist pre-Ramadan for ALL insulin-using patients

Cultural Considerations for GCC Diabetes Nursing ▼

Many GCC patients prefer traditional herbal remedies — assess for interactions (eg. fenugreek, black seed/Nigella sativa may have mild glucose-lowering effects)
Family involvement is central — engage family in diabetes education (GCC collective decision-making culture)
Dietary advice must account for GCC food culture: dates (high GI), rice, bread; portion control education culturally adapted
Modesty considerations for physical examination (foot exam, injection site inspection) — ensure same-gender care where possible
Hajj/Umrah: increased walking activity, dietary changes, medication timing disruption — pre-pilgrimage diabetes assessment recommended
Heat and desert climate: increased risk of dehydration, hypoglycaemia unawareness in extreme heat

High-Yield Exam Facts for DHA / DOH / HAAD / SCFHS / QCHP

Diagnostic: FPG ≥7.0 mmol/L OR 2h OGTT ≥11.1 mmol/L OR HbA1c ≥48 mmol/mol (≥6.5%)
Metformin: HOLD if eGFR <30, contrast, surgery, sick day (SADMAN)
SGLT2i: STOP 3 days before surgery — risk of euglycaemic DKA
Hypoglycaemia = BGL <4.0 mmol/L; conscious = 15g carbs + recheck 15 min
Unconscious hypoglycaemia: IV dextrose 10% 150 mL OR glucagon IM 1 mg
HbA1c target: <53 mmol/mol (7%) general; <64 (8%) elderly/frail; <48 (6.5%) young/tight control
SADMAN: Stop Sulphonylureas, ACEi, Diuretics, Metformin, ARBs, NSAIDs when unwell/dehydrated
Diabetic foot Wagner Grade 3+ = hospitalisation required
Annual screening: HbA1c, lipids, eGFR, ACR, retinal exam, foot exam
Ramadan: sulphonylureas carry highest hypoglycaemia risk; consult diabetologist pre-Ramadan for insulin users
Vitamin B12 monitoring required in long-term metformin users

Practice MCQs

1. A 58-year-old patient with T2DM presents with BGL 3.2 mmol/L and is conscious and able to swallow. What is the most appropriate immediate treatment?

A. Administer glucagon IM 1 mg

B. IV dextrose 50% 50 mL stat

C. 15g rapid-acting carbohydrate (e.g., 150 mL orange juice), recheck at 15 minutes

D. Withhold next dose of insulin and monitor

Correct: C. The "Rule of 15" applies — 15g rapid carbohydrate for a conscious hypoglycaemic patient, then recheck at 15 minutes. Glucagon and IV dextrose are reserved for unconscious/severely hypoglycaemic patients.

2. A nurse is reviewing medications for a patient with T2DM who develops acute gastroenteritis with vomiting and diarrhoea. Which medication should be WITHHELD according to sick day rules?

A. Empagliflozin only

B. Metformin, ACE inhibitor, and sulphonylurea (SADMAN rule)

C. Insulin basal dose only

D. GLP-1 receptor agonist only

Correct: B. SADMAN — Sulphonylureas, ACEi, Diuretics, Metformin, ARBs, and NSAIDs should all be withheld during acute illness/dehydration. Insulin should never be completely stopped.

3. Which HbA1c target is most appropriate for a 75-year-old frail patient with T2DM, multiple comorbidities, and a history of hypoglycaemia unawareness?

A. <48 mmol/mol (6.5%)

B. <53 mmol/mol (7%)

C. <64 mmol/mol (8%)

D. <75 mmol/mol (9%)

Correct: C. For elderly, frail, or complex patients with hypoglycaemia risk, the HbA1c target is relaxed to <64 mmol/mol (8%) to prevent dangerous hypoglycaemic episodes while maintaining reasonable glucose control.

4. During Ramadan, a Muslim patient with T2DM on a sulphonylurea is at highest risk of hypoglycaemia at which time?

A. Immediately after Iftar (breaking fast)

B. In the late afternoon (pre-sunset, during the fasting period)

C. At midnight

D. During Suhoor (pre-dawn meal)

Correct: B. Sulphonylureas stimulate insulin release regardless of food intake. Hypoglycaemia risk is highest during the fasting period, particularly in the late afternoon (pre-sunset) when glucose reserves are depleted. Dose should be reduced by 50% and taken at Iftar only.